Outcome of the meeting of the Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 to inter-alia approve the appointment of Ms. Gowree Gokhale ....
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's Board, at its meeting on March 27, 2026, approved the appointment of Ms. Gowree Gokhale as a Non-Executive and Independent Director for a 5-year term from April 1, 2026 to March 31, 2031, subject to shareholder approval via postal ballot. Ms. Gokhale is a 62-year-old solicitor with over 30 years of legal experience, formerly associated with Nishith Desai Associates for 22 years. In a related change, Ms. Sandra Martyres will complete her second and final term as Independent Director on April 18, 2026, and will cease to be a Director of the company from that date. The Board recorded its appreciation for Ms. Martyres' contributions during her tenure.
This is a routine, well-managed board transition with a like-for-like replacement of an Independent Director. No material impact on operations or shareholder value is expected; the new appointee brings strong legal and pharma-sector expertise to the board.